COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know:

Guidance for cancer researchers:

Get the latest public health information from CDC:

Get the latest research information from NIH:

Emily Boja, Ph.D.

Program Director

Emily Boja

Dr. Boja joined the Office of Clinical Proteomics Cancer Research (OCCPR) at the National Cancer Institute (NCI) in 2009 as a Program Director for the Clinial Proteomic Tumor Analysis Consortium (CPTAC) program, whose overall goals are to improve the understanding of tumor biology, predict drug response to therapy, and reveal the mechanisms of drug resistance. Due to her diverse scientific background ranging from biochemistry, proteomics, and systems/structural biology, she provides scientific expertise and programmatic leadership in managing large-scale proteogenomic studies of human cancers, as well as exploring emerging technologies and scientific disciplines to be integrated into the CPTAC portfilio (e.g., single cell proteomics, neoantigen identification and validation, targeted proteomic assays). She also oversees the analytical, informatics and regulatory aspects of molecular diagnostics and therapeutics in collaboration with the U.S. Food and Drug Administration (FDA) and the American Association of Clinical Chemistry (AACC). For example, helped understanding regulatory science by applying targeted proteomic assays in the clinic, and led the launch of the first precisionFDA-NCI-CPTAC-DREAM's "Multi-Omics Enabled Sample Mislabeling Correction Challenge." Prior to the National Cancer Institute, Dr. Boja served as a Staff Scientist at the Laboratory of Cardiac Energetics where she led studies on the role of mammalian mitochonrial proteogenomics and phosphorylation in OXPHOS and cardiac energetics, following the completion of her postdoctoral Research Fellow training at the Laboratory of Biophysical Chemistry, National Heart, Lung and BIood Institute (intramural programs), NIH. Her expertise originates from her research on key enzymes and pathways involved in one-carbon metabolism, focusing on the structure-functional relationship and the regulation of serine hydroxymethyl transferase activity on serine synthesis pathways and the impact of its dysregulation on cancer, and later high throughput comprehensive proteomic studies of biological systems such as renal cells, heart mitochondria, as well as targeted proteomic assays. Dr. Boja holds a Ph.D. degree in Biochemistry and Molecular Biology (1999) from the Medical College of Virginia, Virginia Commonwealth University. Dr. Boja has co-authored many publications in peer-reviewed journals on enzymology, biochemistry, proteomics and proteogenomics, mentored various undergraduate and graduate level students as a Staff Scientist, and served on an oversight committee of NINDS Proteomics Core Facility, and also many technical evaluation panels for proposals.